Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies MUSCLE & NERVE Lin, P. T., Martin, B. A., Weinacker, A. B., So, Y. T. 2006; 33 (3): 433-435

Abstract

We describe a 48-year-old woman with seronegative myasthenia gravis (MG) and high-titer of anti-MuSK antibody. She had severe bulbar and respiratory weakness with minimal limb weakness for 2 years. Her disease responded poorly to all the conventional immunosuppressive regimens. Treatment with immunoablative dose of cyclophosphamide led to dramatic and sustained remission of her symptoms. High-dose cyclophosphamide is an effective alternative in patients with unusually refractory disease.

View details for DOI 10.1002/mus.20411

View details for PubMedID 16116645